MetaVia Reports Progress in Obesity and MASH Treatments

Neurobo Pharmaceuticals, Inc. ( (MTVA) ) has released its Q1 earnings. Here is a breakdown of the information Neurobo Pharmaceuticals, Inc. presented to its investors.

MetaVia Inc. is a clinical-stage biotechnology company dedicated to transforming cardiometabolic diseases through innovative treatments, focusing on obesity and metabolic dysfunction-associated steatohepatitis (MASH).

In its first quarter of 2025, MetaVia reported significant advancements in its clinical trials and financial health. The company announced positive top-line results from its Phase 1 trial of DA-1726 for obesity, showcasing its potential as a best-in-class therapy. Additionally, MetaVia successfully completed a private placement, raising $10 million to support its operations into 2026.

Key highlights from the earnings report include the promising results of DA-1726, which demonstrated compelling weight loss and glucose control without significant adverse effects. The trial showed a maximum weight reduction of 6.3% and a mean reduction of 4.3% at a 32 mg dose. Furthermore, DA-1241, another of MetaVia’s assets, showed significant improvements in liver health and glycemic control in a Phase 2a trial for MASH, indicating its potential beyond glucose regulation.

Financially, MetaVia reduced its net loss to $3.7 million from $6.7 million in the previous year, attributed to decreased research and development expenses. The company’s cash position, bolstered by the private placement, stands at $11.2 million, ensuring funding into 2026.

Looking ahead, MetaVia plans to explore higher-dose cohorts for DA-1726 to determine the maximum tolerated dose and further develop DA-1241 for MASH. The company remains focused on delivering effective treatments for patients with cardiometabolic diseases, guided by FDA recommendations.